CureDuchenne to Host Webinar with Santhera Pharmaceuticals on SIDEROS Trial
NEWPORT BEACH, Calif., June 14, 2017 – CureDuchenne, a nonprofit dedicated to funding research and improving patient care for Duchenne muscular dystrophy, will host a webinar with Santhera Pharmaceuticals on June 22 at noon ET/9 a.m. PT. Santhera will provide an update about the ongoing SIDEROS trial, which is a trial of their investigational candidate idebenone, in boys currently taking steroids.
The SIDEROS trial is a phase III, double-blind, randomized, placebo-controlled trial that evaluates the efficacy, safety and tolerability of idebenone (administered as oral tablets) in slowing the rate of respiratory function decline in 266 boys with DMD. Patients with reduced respiratory function on any stable glucocorticoid treatment regimen are eligible, regardless of their underlying dystrophin mutation or ambulatory status.
Thomas Meier, PhD, CEO of Santhera Pharmaceuticals and Jodi Wolff, PhD, Director Patient Advocacy, Santhera Pharmaceuticals will present during the webinar. The session will be moderated by Mike Kelly, PhD, Chief Scientific Advisor, CureDuchenne.
To register for the webinar on June 22, click here. The call-in number is (888) 378-4398 and the pass code is 224091. For additional information about the SIDEROS clinical trial, visit www.clinicaltrials.gov.
CureDuchenne was founded in 2003 with a focus on saving the lives of those with Duchenne muscular dystrophy, a disease that affects more than 300,000 boys worldwide. With support from CureDuchenne, nine research projects have advanced to human clinical trials. CureDuchenne also is the innovator bringing physical therapy and standard of care to local communities around the country through CureDuchenne Cares. For more information, please visit CureDuchenne.org and follow us on Facebook, Twitter, Instagram and YouTube.
Santhera Pharmaceuticals (SIX: SANN) is a Swiss specialty pharmaceutical company focused on the
development and commercialization of innovative pharmaceutical products for the treatment of orphan mitochondrial and neuromuscular diseases. Santhera’s lead product RAXONE® (idebenone) is authorized in the European Union, Norway, Iceland and Liechtenstein for the treatment of Leber’s hereditary optic neuropathy (LHON). For Duchenne muscular dystrophy (DMD), Santhera has filed a Marketing Authorization Application (MAA) in the European Union and Switzerland for DMD patients with respiratory function decline who are not taking concomitant steroids. In collaboration with the U.S. National Institute of Neurological Disorders and Stroke (NINDS), Santhera is developing RAXONE® in a third indication, primary progressive multiple sclerosis (PPMS), and omigapil for congenital muscular dystrophy (CMD), all areas of high unmet medical need. For further information, please visit the Company’s website www.santhera.com.
RAXONE® is a trademark of Santhera Pharmaceuticals.